Evaluation O O O O
of O O O O
Safety O O O O
and O O O O
Immunogenicity O O O O
of O O O O
BNT162B2 O O O O
mRNA O O O O
COVID-19 O O O O
Vaccine O O O O
in O O O O
IBD O O O O
Pediatric O O O O
Distinct O O O O
Immune O O O O
Suppressive O O O O
Regimens O O O O
20-30% O O O O
of O O O O
cases O O O O
presenting O O O O
before O O O O
the O O O O
age O O O O
of O O O O
20 O O O O
[ O O O O
[2](#B2-vaccines-10-01109)]. O O O O
Whereas O O O O
the O O O O
safety O O O O
of O O O O
several O O O O
vaccinations O O O O
was O O O O
proved O O O O
in O O O O
IBD O O O O
patients O O O O
[ O O O O
[3](#B3-vaccines-10-01109)], O O O O
immunogenicity O O O O
toward O O O O
hepatitis O O O O
B, O O O O
hepatitis O O O O
A, O O O O
pneumococcal, O O O O
and O O O O
influenza O O O O
vaccination O O O O
was O O O O
variably O O O O
affected O O O O
according O O O O
vaccination O O O O
immunogenicity O O O O
revealed O O O O
that O O O O
IBD O O O O
adult O O O O
patients O O O O
treated O O O O
with O O O O
the O O O O
anti-tumor O O O O
necrosis O O O O
factor O O O O
(anti-TNF) O O O O
drugs O O O O
(Infliximab O O O O
(Janssen, O O O O
Horsham, O O O O
PA, O O O O
USA), O O O O
or O O O O
Adalimumab O O O O
(Abbvie, O O O O
North O O O O
Chicago, O O O O
IL, O O O O
USA)) O O O O
developed O O O O
a O O O O
reduced O O O O
immune O O O O
response O O O O
to O O O O
SARS-CoV-2 O O O O
vaccine, O O O O
either O O O O
BNT162b2 O O O O
(Pfizer-Biontech, O O O O
Mainz, O O O O
Germany) O O O O
or O O O O
mRNA-1273 O O O O
(Moderna, O O O O
Cambridge, O O O O
MA, O O O O
healthy O O O O
controls O O O O
(HC). O O O O
[20](#B20-vaccines-10-01109). O O O O
However, Reason 4 O O
despite Reason 4 O O
the Reason 4 O O
increasing Reason 4 O O
extent Reason 4 O O
of Reason 4 O O
SARS-CoV-2 Reason 4 O O
vaccination Reason 4 O O
among Reason 4 O O
children, Reason 4 O O
little Reason 4 O O
is Reason 4 O O
known Reason 4 O O
about Reason 4 O O
safety Reason 4 O O
and Reason 4 O O
efficacy Reason 4 O O
in Reason 4 O O
children Reason 4 O O
and Reason 4 O O
adolescents Reason 4 O O
with Reason 4 O O
IBD Reason 4 O O
(pIBD) Reason 4 O O
[ Reason 4 O O
[21](#B21-vaccines-10-01109), Reason 4 O O
[22](#B22-vaccines-10-01109)] Reason 4 O O
who Reason 4 O O
are Reason 4 O O
at Reason 4 O O
increased Reason 4 O O
risk Reason 4 O O
SARS-CoV-2 Reason 4 O O
infection Reason 4 O O
and Reason 4 O O
SARS-CoV-2-induced Reason 4 O O
disease Reason 4 O O
relapses Reason 4 O O
[ Reason 4 O O
[23](#B23-vaccines-10-01109)]. Reason 4 O O
[24](#B24-vaccines-10-01109)]. Reason 4 O O
2. Reason 4 O O
Materials Reason 4 O O
and Reason 4 O O
Methods Reason 4 O O
2.1. Reason 4 O O
Study Reason 4 O O
Participants Reason 4 O O
[25](#B25-vaccines-10-01109)]. Reason 4 O O
Health-care Reason 4 O O
workers Reason 4 O O
who Reason 4 O O
received Reason 4 O O
BNT162b2 Reason 4 O O
mRNA Reason 4 O O
COVID-19 Reason 4 O O
vaccine Reason 4 O O
were Reason 4 O O
used Reason 4 O O
as Reason 4 O O
control Reason 4 O O
group Reason 4 O O
(HC). Reason 4 O O
All Reason 4 O O
participants Reason 4 O O
received Reason 4 O O
a Reason 4 O O
questionnaire Reason 4 O O
about Reason 4 O O
the Reason 4 O O
adverse Reason 4 O O
events Reason 4 O O
and Reason 4 O O
side Reason 4 O O
effects Reason 4 O O
following Reason 4 O O
each Reason 4 O O
dose Reason 4 O O
of Reason 4 O O
vaccine. Reason 4 O O
All Reason 4 O O
procedures Reason 4 O O
performed Reason 4 O O
in Reason 4 O O
the Reason 4 O O
study Reason 4 O O
were Reason 4 O O
in Reason 4 O O
accordance Reason 4 O O
with Reason 4 O O
the Reason 4 O O
ethical Reason 4 O O
standards Reason 4 O O
of Reason 4 O O
the Reason 4 O O
institutional Reason 4 O O
research Reason 4 O O
committee Reason 4 O O
and Reason 4 O O
with Reason 4 O O
the Reason 4 O O
1964 Reason 4 O O
Helsinki Reason 4 O O
declaration Reason 4 O O
and Reason 4 O O
its Reason 4 O O
later Reason 4 O O
amendments. Reason 4 O O
Local Reason 4 O O
ethical Reason 4 O O
committee Reason 4 O O
approved Reason 4 O O
the Reason 4 O O
study Reason 4 O O
and Reason 4 O O
written Reason 4 O O
informed Reason 4 O O
consent Reason 4 O O
was Reason 4 O O
obtained Reason 4 O O
from Reason 4 O O
all Reason 4 O O
participants Reason 4 O O
or Reason 4 O O
legal Reason 4 O O
guardians. Reason 4 O O
Age, Reason 4 O O
gender, Reason 4 O O
and Reason 4 O O
clinical Reason 4 O O
characteristics Reason 4 O O
of Reason 4 O O
the Reason 4 O O
cohorts Reason 4 O O
are Reason 4 O O
described Reason 4 O O
in Reason 4 O O
[Table Reason 4 O O
1](#vaccines-10-01109-t001). Reason 4 O O
2.2. Reason 4 O O
Safety Reason 4 O O
[26](#B26-vaccines-10-01109)] Reason 4 O O
were Reason 4 O O
reported Reason 4 O O
to Reason 4 O O
the Reason 4 O O
unit Reason 4 O O
of Reason 4 O O
occupational Reason 4 O O
medicine Reason 4 O O
by Reason 4 O O
the Reason 4 O O
employees Reason 4 O O
enrolled. Reason 4 O O
2.3. Reason 4 O O
Sample Reason 4 O O
Collection Reason 4 O O
and Reason 4 O O
Storage Reason 4 O O
2.4. Reason 4 O O
Humoral Reason 4 O O
Response Reason 4 O O
[27](#B27-vaccines-10-01109)] Reason 4 O O
at Reason 4 O O
T0, Reason 4 O O
T21 Reason 4 O O
and Reason 4 O O
T28. Reason 4 O O
In Reason 4 O O
particular, Reason 4 O O
we Reason 4 O O
measured Reason 4 O O
Ab Reason 4 O O
against Reason 4 O O
the Reason 4 O O
S1-receptor-binding-domain Reason 4 O O
(RBD) Reason 4 O O
(Roche Reason 4 O O
(Basel, Reason 4 O O
Switzerland) Reason 4 O O
2.5. Reason 4 O O
Quantification Reason 4 O O
and Reason 4 O O
Statistical Reason 4 O O
Analysis Reason 4 O O
[28](#B28-vaccines-10-01109)]. Reason 4 O O
All Reason 4 O O
variables Reason 4 O O
included Reason 4 O O
in Reason 4 O O
the Reason 4 O O
analysis Reason 4 O O
were Reason 4 O O
not Reason 4 O O
normally Reason 4 O O
distributed. Reason 4 O O
Statistical Reason 4 O O
tests Reason 4 O O
were Reason 4 O O
chosen Reason 4 O O
according Reason 4 O O
to Reason 4 O O
data Reason 4 O O
distribution Reason 4 O O
in Reason 4 O O
terms Reason 4 O O
of Reason 4 O O
normality, Reason 4 O O
skewness, Reason 4 O O
and Reason 4 O O
dysomogeneity Reason 4 O O
of Reason 4 O O
variances. Reason 4 O O
In Reason 4 O O
line Reason 4 O O
with Reason 4 O O
this, Reason 4 O O
as Reason 4 O O
indicated Reason 4 O O
in Reason 4 O O
the Reason 4 O O
figure Reason 4 O O
legends, Reason 4 O O
non-parametric Reason 4 O O
paired Reason 4 O O
test Reason 4 O O
(Wilcoxon Reason 4 O O
Signed Reason 4 O O
Rank Reason 4 O O
Test) Reason 4 O O
was Reason 4 O O
used Reason 4 O O
to Reason 4 O O
assess Reason 4 O O
differences Reason 4 O O
between Reason 4 O O
Ab Reason 4 O O
load Reason 4 O O
at Reason 4 O O
the Reason 4 O O
different Reason 4 O O
time Reason 4 O O
points, Reason 4 O O
whereas Reason 4 O O
non-parametric Reason 4 O O
unpaired Reason 4 O O
test Reason 4 O O
(Mann-Whitney Reason 4 O O
test) Reason 4 O O
was Reason 4 O O
used Reason 4 O O
for Reason 4 O O
comparison Reason 4 O O
between Reason 4 O O
pIBD Reason 4 O O
and Reason 4 O O
HC Reason 4 O O
and Reason 4 O O
also Reason 4 O O
between Reason 4 O O
pIBD Reason 4 O O
on Reason 4 O O
therapy Reason 4 O O
with Reason 4 O O
anti-TNF Reason 4 O O
and Reason 4 O O
patients Reason 4 O O
receiving Reason 4 O O
other Reason 4 O O
treatments. Reason 4 O O
3. Reason 4 O O
Results Reason 4 O O
3.1. Reason 4 O O
Patient Reason 4 O O
Characteristics Reason 4 O O
[Table Reason 4 O O
1](#vaccines-10-01109-t001). Reason 4 O O
At Reason 4 O O
every Reason 4 O O
follow-up Reason 4 O O
visit Reason 4 O O
(every Reason 4 O O
2-3 Reason 4 O O
months) Reason 4 O O
during Reason 4 O O
the Reason 4 O O
course Reason 4 O O
of Reason 4 O O
the Reason 4 O O
pandemics, Reason 4 O O
all Reason 4 O O
patients Reason 4 O O
performed Reason 4 O O
nasopharyngeal Reason 4 O O
swab Reason 4 O O
(NPS) Reason 4 O O
screening Reason 4 O O
for Reason 4 O O
SARS-CoV2 Reason 4 O O
infection. Reason 4 O O
No Reason 4 O O
infections Reason 4 O O
were Reason 4 O O
detected Reason 4 O O
during Reason 4 O O
the Reason 4 O O
follow-up Reason 4 O O
period. Reason 4 O O
Among Reason 4 O O
the Reason 4 O O
pIBD, Reason 4 O O
14 Reason 4 O O
patients Reason 4 O O
out Reason 4 O O
of Reason 4 O O
27 Reason 4 O O
were Reason 4 O O
on Reason 4 O O
therapy Reason 4 O O
with Reason 4 O O
anti-TNF Reason 4 O O
(mean Reason 4 O O
age Reason 4 O O
15.6 Reason 4 O O
years Reason 4 O O
with Reason 4 O O
agerange Reason 4 O O
12.5-20.2 Reason 4 O O
years, Reason 4 O O
and Reason 4 O O
with Reason 4 O O
4 Reason 4 O O
patients Reason 4 O O
older Reason 4 O O
than Reason 4 O O
18). Reason 4 O O
No Reason 4 O O
differences Reason 4 O O
in Reason 4 O O
terms Reason 4 O O
of Reason 4 O O
age Reason 4 O O
were Reason 4 O O
found Reason 4 O O
between Reason 4 O O
patients Reason 4 O O
on Reason 4 O O
anti-TNF Reason 4 O O
compared Reason 4 O O
to Reason 4 O O
the Reason 4 O O
other Reason 4 O O
group Reason 4 O O
(data Reason 4 O O
not Reason 4 O O
shown). Reason 4 O O
As Reason 4 O O
shown Reason 4 O O
in Reason 4 O O
[Table Reason 4 O O
1](#vaccines-10-01109-t001), Reason 4 O O
age Reason 4 O O
at Reason 4 O O
vaccination Reason 4 O O
was Reason 4 O O
significantly Reason 4 O O
higher Reason 4 O O
in Reason 4 O O
HC Reason 4 O O
(p Reason 4 O O
= Reason 4 O O
0.0001). Reason 4 O O
No Reason 4 O O
differences Reason 4 O O
related Reason 4 O O
to Reason 4 O O
gender Reason 4 O O
were Reason 4 O O
found Reason 4 O O
between Reason 4 O O
the Reason 4 O O
groups. Reason 4 O O
3.2. Reason 4 O O
Safety Reason 4 O O
of Reason 4 O O
2 Reason 4 O O
Doses Reason 4 O O
of Reason 4 O O
BNT162B2 Reason 4 O O
mRNA Reason 4 O O
COVID-19 Reason 4 O O
Vaccine Reason 4 O O
[Table Reason 4 O O
2](#vaccines-10-01109-t002)). Reason 4 O O
The Reason 4 O O
majority Reason 4 O O
of Reason 4 O O
patients Reason 4 O O
reported Reason 4 O O
mild-to-moderate Reason 4 O O
systemic Reason 4 O O
reactions; Reason 4 O O
however, Reason 4 O O
only Reason 4 O O
one Reason 4 O O
patient Reason 4 O O
reported Reason 4 O O
severe Reason 4 O O
cold-like Reason 4 O O
symptoms Reason 4 O O
and Reason 4 O O
asthenia Reason 4 O O
after Reason 4 O O
the Reason 4 O O
second Reason 4 O O
dose. Reason 4 O O
The Reason 4 O O
most Reason 4 O O
commonly Reason 4 O O
reported Reason 4 O O
systemic Reason 4 O O
reactions Reason 4 O O
after Reason 4 O O
the Reason 4 O O
first Reason 4 O O
dose Reason 4 O O
were Reason 4 O O
cold-like Reason 4 O O
symptoms Reason 4 O O
and Reason 4 O O
myalgia, Reason 4 O O
described, Reason 4 O O
respectively, Reason 4 O O
in Reason 4 O O
22.2% Reason 4 O O
and Reason 4 O O
25.9% Reason 4 O O
of Reason 4 O O
the Reason 4 O O
patients. Reason 4 O O
Instead, Reason 4 O O
the Reason 4 O O
most Reason 4 O O
frequent Reason 4 O O
systemic Reason 4 O O
reaction Reason 4 O O
after Reason 4 O O
the Reason 4 O O
second Reason 4 O O
dose Reason 4 O O
was Reason 4 O O
asthenia, Reason 4 O O
reported Reason 4 O O
in Reason 4 O O
33.3% Reason 4 O O
of Reason 4 O O
the Reason 4 O O
patients, Reason 4 O O
and Reason 4 O O
myalgia Reason 4 O O
and Reason 4 O O
headache, Reason 4 O O
reported Reason 4 O O
in Reason 4 O O
22.2% Reason 4 O O
of Reason 4 O O
the Reason 4 O O
patients. Reason 4 O O
Only Reason 4 O O
one Reason 4 O O
patient Reason 4 O O
after Reason 4 O O
the Reason 4 O O
first Reason 4 O O
and Reason 4 O O
the Reason 4 O O
second Reason 4 O O
dose Reason 4 O O
reported Reason 4 O O
the Reason 4 O O
self-administration Reason 4 O O
of Reason 4 O O
anti-inflammatory Reason 4 O O
treatments. Reason 4 O O
No O O O O
patients O O O O
were O O O O
hospitalized O O O O
due O O O O
to O O O O
adverse O O O O
reactions. O O O O
3.3. O O O O
Serologic O O O O
Response O O O O
[Figure O O O O
1](#vaccines-10-01109-f001)both O O O O
the O O O O
pIBD O O O O
and O O O O
HC O O O O
groups O O O O
experienced O O O O
a O O O O
statistically O O O O
significant O O O O
increase O O O O
in O O O O
anti-SARS-CoV-2 O O O O
Abs O O O O
after O O O O
both O O O O
the O O O O
first O O O O
and O O O O
second O O O O
vaccination O O O O
dose O O O O
(p O O O O
< O O O O
0.0001). O O O O
[Figure O O O O
1](#vaccines-10-01109-f001)). O O O O
[Figure O O O O
2](#vaccines-10-01109-f002)). O O O O
4. O O O O
Discussion O O O O
[23](#B23-vaccines-10-01109)]. O O O O
Through Reason 2 O O
a Reason 2 O O
long-term Reason 2 O O
follow-up Reason 2 O O
after Reason 2 O O
vaccination, Reason 2 O O
we Reason 2 O O
here Reason 2 O O
investigated Reason 2 O O
whether Reason 2 O O
SARS-CoV-2 Reason 2 O O
vaccination Reason 2 O O
could Reason 2 O O
impact Reason 2 O O
on Reason 2 O O
the Reason 2 O O
rate Reason 2 O O
of Reason 2 O O
IBD Reason 2 O O
flares Reason 2 O O
over Reason 2 O O
time. Reason 2 O O
According O O O O
to O O O O
what O O O O
was O O O O
previously O O O O
found O O O O
in O O O O
adults, O O O O
who O O O O
showed O O O O
no O O O O
increased O O O O
risk O O O O
of O O O O
short-term O O O O
adverse O O O O
effects O O O O
[ O O O O
vaccination, O O O O
early O O O O
patients O O O O
out O O O O
of O O O O
27 O O O O
(18.5%) O O O O
showed O O O O
an O O O O
IBD O O O O
exacerbation O O O O
after O O O O
SARS-CoV-2 O O O O
vaccination. O O O O
However, O O O O
among O O O O
these O O O O
patients, O O O O
two O O O O
already O O O O
had O O O O
a O O O O
clinical O O O O
history O O O O
of O O O O
recurrent O O O O
disease O O O O
relapse. O O O O
Thus, Reason 3 O O
no Reason 3 O O
causal Reason 3 O O
correlation Reason 3 O O
between Reason 3 O O
primary Reason 3 O O
disease Reason 3 O O
exacerbation Reason 3 O O
and Reason 3 O O
SARS-CoV-2 Reason 3 O O
vaccination Reason 3 O O
could Reason 3 O O
be Reason 3 O O
established Reason 3 O O
in Reason 3 O O
our Reason 3 O O
cohort, Reason 3 O O
highlighting Reason 3 O O
the Reason 3 O O
critical Reason 3 O O
importance Reason 3 O O
of Reason 3 O O
additional Reason 3 O O
studies Reason 3 O O
characterized Reason 3 O O
by Reason 3 O O
a Reason 3 O O
larger Reason 3 O O
sample Reason 3 O O
size Reason 3 O O
of Reason 3 O O
pIBD Reason 3 O O
and Reason 3 O O
longer Reason 3 O O
follow-up. Reason 3 O O
[23](#B23-vaccines-10-01109), O O O O
[34](#B34-vaccines-10-01109)]. O O O O
The Reason 4 O O
advent Reason 4 O O
of Reason 4 O O
SARS-CoV-2 Reason 4 O O
vaccination Reason 4 O O
represents Reason 4 O O
a Reason 4 O O
crucial Reason 4 O O
milestone Reason 4 O O
in Reason 4 O O
the Reason 4 O O
history Reason 4 O O
of Reason 4 O O
pandemics, Reason 4 O O
especially Reason 4 O O
for Reason 4 O O
patients Reason 4 O O
with Reason 4 O O
acquired Reason 4 O O
immune Reason 4 O O
deficiencies, Reason 4 O O
due Reason 4 O O
to Reason 4 O O
ongoing Reason 4 O O
immune-suppressive Reason 4 O O
treatments. Reason 4 O O
However, Reason 4 O O
large Reason 4 O O
hesitation Reason 4 O O
from Reason 4 O O
the Reason 4 O O
IBD Reason 4 O O
adult Reason 4 O O
community Reason 4 O O
towards Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
intervention Reason 4 O O
for Reason 4 O O
both Reason 4 O O
safety Reason 4 O O
and Reason 4 O O
immunogenicity Reason 4 O O
reasons Reason 4 O O
was Reason 4 O O
noted Reason 4 O O
at Reason 4 O O
the Reason 4 O O
beginning Reason 4 O O
of Reason 4 O O
the Reason 4 O O
vaccination Reason 4 O O
campaign Reason 4 O O
[ Reason 4 O O
[29](#B29-vaccines-10-01109), Reason 4 O O
[35](#B35-vaccines-10-01109)]. Reason 4 O O
[36](#B36-vaccines-10-01109)]. Reason 4 O O
The O O O O
independent O O O O
impact O O O O
of O O O O
age O O O O
on O O O O
immunogenicity O O O O
was O O O O
also O O O O
confirmed O O O O
in O O O O
multiple O O O O
adult O O O O
IBD O O O O
cohorts O O O O
[ O O O O
[15](#B15-vaccines-10-01109), O O O O
[17](#B17-vaccines-10-01109)] O O O O
and O O O O
by O O O O
our O O O O
group O O O O
in O O O O
another O O O O
cohort O O O O
[ O O O O
[37](#B37-vaccines-10-01109)]. O O O O
[13](#B13-vaccines-10-01109), O O O O
[14](#B14-vaccines-10-01109), O O O O
[15](#B15-vaccines-10-01109), O O O O
[16](#B16-vaccines-10-01109), O O O O
[17](#B17-vaccines-10-01109), O O O O
[18](#B18-vaccines-10-01109)]. O O O O
For Reason 3 O O
the Reason 3 O O
first Reason 3 O O
time Reason 3 O O
in Reason 3 O O
the Reason 3 O O
pediatric Reason 3 O O
context, Reason 3 O O
we Reason 3 O O
confirmed Reason 3 O O
such Reason 3 O O
findings, Reason 3 O O
showing Reason 3 O O
that Reason 3 O O
pIBD Reason 3 O O
on Reason 3 O O
therapy Reason 3 O O
with Reason 3 O O
anti-TNF Reason 3 O O
(Infliximab Reason 3 O O
or Reason 3 O O
Adalimumab) Reason 3 O O
developed Reason 3 O O
a Reason 3 O O
lower Reason 3 O O
response Reason 3 O O
in Reason 3 O O
terms Reason 3 O O
of Reason 3 O O
Anti-S Reason 3 O O
ab Reason 3 O O
compared Reason 3 O O
to Reason 3 O O
patients Reason 3 O O
receiving Reason 3 O O
Azathioprine Reason 3 O O
or Reason 3 O O
Mesalazine. Reason 3 O O
In O O O O
contrast O O O O
with O O O O
these O O O O
results, O O O O
showing O O O O
no O O O O
effect O O O O
of O O O O
azathioprine O O O O
on O O O O
SARS-CoV-2 O O O O
vaccination O O O O
immunogenicity, O O O O
the O O O O
negative O O O O
influence O O O O
of O O O O
another O O O O
antimetabolite, O O O O
the O O O O
mycophenolate, O O O O
was O O O O
recently O O O O
shown O O O O
in O O O O
a O O O O
cohort O O O O
of O O O O
solid-organ-transplanted O O O O
adolescents O O O O
and O O O O
young O O O O
adults O O O O
[ O O O O
[38](#B38-vaccines-10-01109)] O O O O
